

All Chief Executives

All Medical Directors

All Chief Pharmacists

Specialised Commissioning South West
NHS England
100 Temple Street
Bristol
BS1 6AG
Email: england.speccomm-southwest@nhs.net

17 April 2025

Dear Colleagues,

**Re: Switching immunoglobulin products under the new framework in 2025:
Patient Information Sheet**

As described in the letter sent in February 2025 (SSC2784), there will be several changes to the supply of immunoglobulin products in England in 2025, aimed at increasing self-sufficiency and ensuring more reliable product availability. The new framework will result in changes to the availability of some existing immunoglobulin brands and the introduction of several new brands.


- Some brands of immunoglobulins which have previously been commonly prescribed will no longer be available for routine use.
- Both intravenous and subcutaneous therapy are affected by this change.

Patients who are currently being treated with a brand of immunoglobulin that is no longer available will need to switch to an alternative brand.


A patient information sheet has been developed to outline the changes to the range of immunoglobulin products available on the NHS. It is intended to support patients who rely on immunoglobulin treatment and may be required to switch to a different immunoglobulin product. The BSI Clinical Immunology Professional Network (BSI-CIPN) has also produced a short guidance document on managing these changes for immunology teams, which can be found here [BSI-CIPN guidance immunoglobulin product switching 0.pdf](#).

Please cascade the attached patient information sheet to relevant clinical teams within your organisation to support communication with patients and also direct them to the BSI-CIPN guidance.

With best wishes,



Emma Redfern
Medical Director NHS England South West
Region



Tracey Williams
Principal Pharmacist